Cancer immunotherapy by a recombinant phage vaccine displaying EGFR mimotope: an in vivo study

References

• Laskin JJ, Sandler AB. Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev 2004;30:1–17
   PubMed Web of Science ®Google Scholar
• Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Rel Cancer 2001;8:3–9
   PubMed Web of Science ®Google Scholar
• Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241–250
   PubMed Web of Science ®Google Scholar
• Laird AD, Cherrington JM. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin Invest Drugs 2003;12:51–64
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. New Engl J Med 2007;357:2040–2048
   PubMed Web of Science ®Google Scholar
• Peeters M, Balfour J, Arnold D. Review article: panitumumab – a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer. Aliment Pharmacol Ther 2008;28:269–281
   PubMed Web of Science ®Google Scholar
• Waldmann TA. Immunotherapy: past, present and future. Nature Med 2003;9:269–277
   PubMed Web of Science ®Google Scholar
• Baxevanis CN, Perez SA, Papamichail M. Cancer immunotherapy. Crit Rev Clin Lab Sci 2009;46:167–189
   PubMed Web of Science ®Google Scholar
• Jensen KD, Nori A, Tijerina M, et al. Cytoplasmic delivery and nuclear targeting of synthetic macromolecules. J Control Release 2003;87:89–105
   PubMed Web of Science ®Google Scholar
• Liu D, Tang L, Zhou C, Tan L. Immunotherapy of EGFR-positive tumor based on recombinant EGFR phage vaccine. Chin Ger J Clin Oncol 2006;5:189–193
   Google Scholar
• Minev BR, Chavez FL, Mitchell MS. Cancer vaccines: novel approaches and new promise. Pharmacol Ther 1999;81:121–139
   Google Scholar
• Yip YL, Smith G, Koch J, et al. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design. J Immunol 2001;166:5271–5278
   PubMed Web of Science ®Google Scholar
• Riemer AB, Jensen-Jarolim E. Mimotope vaccines: epitope mimics induce anti-cancer antibodies. Immunol Lett 2007;113:1–5
   PubMed Web of Science ®Google Scholar
• Knittelfelder R, Riemer AB, Jensen-Jarolim E. Mimotope vaccination – from allergy to cancer. Expert Opin Biol Ther 2009;9:493–506
   PubMed Web of Science ®Google Scholar
• Kozbor D. Cancer vaccine with mimotopes of tumor-associated carbohydrate antigens. Immunol Res 2010;46:23–31
   PubMed Web of Science ®Google Scholar
• Navari M, Zare M, Javanmardi M, et al. Epitope mapping of epidermal growth factor receptor (EGFR) monoclonal antibody and induction of growth-inhibitory polyclonal antibodies by vaccination with EGFR mimotope. Immunopharmacol Immunotoxicol 2014;36:309–315
   PubMed Web of Science ®Google Scholar
• Hardy B, Raiter A. A mimotope peptide-based anti-cancer vaccine selected by BAT monoclonal antibody. Vaccine 2005;23:4283–4291
   PubMed Web of Science ®Google Scholar
• Li W, Ran Y, Li M, et al. Mimotope vaccination for epitope-specific induction of anti-VEGF antibodies. BMC Biotechnol 2013;13:77
   PubMed Web of Science ®Google Scholar
• Riemer AB, Kurz H, Klinger M, et al. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst 2005;97:1663–1670
   PubMed Web of Science ®Google Scholar
• Brämswig KH, Knittelfelder R, Gruber S, et al. Immunization with mimotopes prevents growth of carcinoembryonic antigen-positive tumors in BALB/c mice. Clin Cancer Res 2007;13:6501–6508
   PubMed Web of Science ®Google Scholar
• Gao J, Wang Y, Liu Z, Wang Z. Phage display and its application in vaccine design. Ann Microbiol 2010;60:13–19
   Google Scholar
• Wan Y, Wu Y, Bian J, et al. Induction of hepatitis B virus-specific cytotoxic T lymphocytes response in vivo by filamentous phage display vaccine. Vaccine 2001;19:2918–2923
   PubMed Web of Science ®Google Scholar
• van Houten NE, Zwick MB, Menendez A, Scott JK. Filamentous phage as an immunogenic carrier to elicit focused antibody responses against a synthetic peptide. Vaccine 2006;24:4188–4200
   PubMed Web of Science ®Google Scholar
• Yip YL, Smith G, Ward RL. Comparison of phage pIII, pVIII and GST as carrier proteins for peptide immunisation in Balb/c mice. Immunol Lett 2001;79:197–202
   Google Scholar
• Burritt JB, Bond CW, Doss KW, Jesaitis AJ. Filamentous phage display of oligopeptide libraries. Anal Biochem 1996;238:1–13
   Google Scholar
• Smith GP, Petrenko VA. Phage display. Chem Rev 1997;97:391–410
   PubMed Web of Science ®Google Scholar
• Duś D, Budzyński W, Radzikowski C. LL2 cell line derived from transplantable murine Lewis lung carcinoma – maintenance in vitro and growth characteristics. Arch Immunol Ther Exp 1985;33:817–823
   PubMed Web of Science ®Google Scholar
• Ramírez BS, Pestana ES, Hidalgo GG, et al. Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant. Int J Cancer 2006;119:2190–2199
   PubMed Web of Science ®Google Scholar
• Hu B, Wei Y, Tian L, et al. Active antitumor immunity elicited by vaccine based on recombinant form of epidermal growth factor receptor. J Immunother 2005;28:236–244
   Google Scholar
• Lu Y, Wei Y-Q, Tian L, et al. Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor. J Immunol 2003;170:3162–3170
   PubMed Web of Science ®Google Scholar
• Kurzepa A, Dabrowska K, Skaradzinski G, Gorski A. Bacteriophage interactions with phagocytes and their potential significance in experimental therapy. Clin Exp Med 2009;9:93–100
   Google Scholar
• Sartorius R, Pisu P, D’Apice L, et al. The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses. J Immunol 2008;180:3719–3728
   PubMed Web of Science ®Google Scholar
• Fang J, Wang G, Yang Q, et al. The potential of phage display virions expressing malignant tumor-specific antigen MAGE-A1 epitope in murine model. Vaccine 2005;23:4860–4866
   PubMed Web of Science ®Google Scholar
• Dabrowska K, Opoloski A, Wietrzyk J, et al. Anticancer activity of bacteriophage T4 and its mutant HAP1 in mouse experimental tumour models. Anticancer Res 2004;24:3991–3996
   Google Scholar